tammikuu 2022

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

Venetoclax plus obinutuzumab has proved to be effective as frontline therapy in patients with Chronic Lymphocytic Leukemia (CLL). In this MEDtalk, Matthew S. Davids presents a trial-in-progress, investigating retreatment responses with venetoclax plus obinutuzumab in patients with relapsed CLL. Matthew is hoping for the results to support a future retreatment regimen for this group of patients.

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Rekisteröidy
Onko sinulla käyttäjätunnukset? Kirjaudu sisään

Back to top

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Aina käytössä

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Preferences

Preference cookies are used to store user preferences to provide content that is customized and convenient for the users, like the language of the website or the location of the visitor.

Cookie	Kesto	Kuvaus
_gat_UA-43794127-5	1 minute	This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Kesto	Kuvaus
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

Lue artikkeli

Asiaan liittyvä sisältö

A clinical perspective of the best combination therapy and MRD guided treatment for patients with CLL

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

The main clinical message from the Five-Year Analysis of Murano Study